Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 8/20 | 0.60 |
| ▸ | CTSS | P25774 | 3/20 | 0.60 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1926493 | 1.00 | CTSK (0.60) | CTSKCTSSNOD1 | |
| SCHEMBL17356699 | 1.00 | CTSK (0.60) | CTSKCTSSNOD1 | |
| SCHEMBL6818249 | 1.00 | CTSK (0.60) | CTSKCTSSNOD1 | |
| SCHEMBL7547359 | 1.00 | CTSK (0.60) | CTSKCTSSNOD1 | |
| SCHEMBL7550254 | 1.00 | CTSK (0.60) | CTSKCTSSNOD1 | |
| SCHEMBL16939058 | 1.00 | CTSK (0.60) | CTSKCTSSNOD1 | |
| SCHEMBL7547354 | 1.00 | CTSK (0.60) | CTSKCTSSNOD1 | |
| SCHEMBL9743599 | 1.00 | CTSK (0.60) | CTSKCTSSNOD1 | |
| SCHEMBL7839929 | 1.00 | CTSK (0.60) | CTSKCTSSNOD1 | |
| SCHEMBL7555646 | 1.00 | CTSK (0.60) | CTSKCTSSNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3541851-A1 | SULPHATED HYALURONIC ACIDS FUNCTIONALISED WITH DOPAMINE | Fidia Farmaceutici S.p.A. (IT) | 2019-09-25 | — | — | EP | disclosed |
| WO-2018092013-A1 | SULPHATED HYALURONIC ACIDS FUNCTIONALISED WITH DOPAMINE | FIDIA FARMACEUTICI S.P.A. (IT) | 2018-05-24 | — | — | WO | disclosed |
| EP-2448930-A1 | COVALENT INHIBITION OF BACTERIAL QUORUM SENSING | The National Institute for Biotechnology in the Negev Ltd. (IL) | 2012-05-09 | — | — | EP | disclosed |
| WO-2009136965-A1 | COMPOSITIONS AND METHODS COMPRISING CAPURAMYCIN ANALOGUES | SEQUELLA, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| WO-2008102127-A2 | GEL FORMING COMPOUNDS | PLIVA HRVATSKA D.O.O. (HR) | 2008-08-28 | — | — | WO | disclosed |
| US-7381717-B2 | Anti-HIV agents with dual sites of action | MEHARRY MEDICAL COLLEGE (US) | 2008-06-03 | — | — | US | disclosed |
| US-20060135495-A1 | Anti-HIV agents with dual sites of action | CHEN CHIN H | 2006-06-22 | — | — | US | disclosed |
| US-7026305-B2 | Anti-HIV agents with dual sites of action | MEHARRY MEDICAL COLLEGE (US) | 2006-04-11 | — | — | US | disclosed |
| US-20040204389-A1 | Anti-HIV agents with dual sites of action | MEHARRY MEDICAL COLLEGE | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135495-A1 | Anti-HIV agents with dual sites of action | SAMHD1, EIF2AK2, HAVCR2 | CTSK 1339/4885CTSS 525/4885NOD1 2979/4885 |
| US-20040204389-A1 | Anti-HIV agents with dual sites of action | CCR5, HAVCR2, SAMHD1 | CTSK 1272/4885CTSS 486/4885NOD1 2648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.